DIA
TVTX icon

Dana Investment Advisors’s Travere Therapeutics TVTX Stock Holding History

Dana Investment Advisors’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-30,801
Closed -$473K – 421
2023
Q2 		$473K Buy
30,801
+6,390
+26% +$116K 0.02% 328
2023
Q1 		$549K Sell
24,411
-949
-4% -$20.2K 0.03% 301
2022
Q4 		$533K Buy
25,360
+5,850
+30% +$124K 0.03% 304
2022
Q3 		$481K Sell
19,510
-876
-4% -$22.6K 0.03% 308
2022
Q2 		$494K Sell
20,386
-489
-2% -$12.3K 0.03% 311
2022
Q1 		$538K Sell
20,875
-173
-0.8% -$4.59K 0.02% 264
2021
Q4 		$653K Sell
21,048
-2,364
-10% -$66.6K 0.03% 242
2021
Q3 		$568K Buy
+23,412
New +$430K 0.03% 239

Other funds holding TVTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Dana Investment Advisors's TVTX Position: Q3 2023 in Review

Dana Investment Advisors sold out of Travere Therapeutics (TVTX) in Q3 2023, closing a stake of 30,801 shares — an estimated $473K sold.

Dana Investment Advisors first reported a position in TVTX in Q3 2021 and held it in 8 quarters. The position peaked at $653K in Q4 2021. 169 funds tracked by Wall St. Rank hold TVTX as of Q3 2023.

  • Dana Investment Advisors reported no remaining Travere Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Dana Investment Advisors sold 30,801 Travere Therapeutics shares in Q3 2023, an estimated $473K.
  • Dana Investment Advisors first reported a position in Travere Therapeutics in Q3 2021 and held it in 8 quarters.
  • Dana Investment Advisors's Travere Therapeutics position peaked at $653K in Q4 2021.
  • 169 funds tracked by Wall St. Rank held Travere Therapeutics as of Q3 2023.

Based on Dana Investment Advisors's 13F filing for Q3 2023, filed 15 Nov 2023.